<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658684</url>
  </required_header>
  <id_info>
    <org_study_id>A0221006</org_study_id>
    <secondary_id>A0221006</secondary_id>
    <nct_id>NCT00658684</nct_id>
  </id_info>
  <brief_title>Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.</brief_title>
  <official_title>An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the long term safety, tolerability and efficacy of fesoterodine in patients with
      OAB.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The number of subjects who experienced AEs (all causality and treatment-related ) based on safety assessment during the study were summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4, 8, 28 and 52</measure>
    <time_frame>Week 4, 8, 28 and 52</time_frame>
    <description>The number of UUI episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of UUI episodes per 24 hours was calculated as the total number of UUI episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Micturitions at Week 4, 8, 28 and 52</measure>
    <time_frame>Week 4, 8, 28 and 52</time_frame>
    <description>The number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of micturitions per 24 hours was calculated as the total number of micturitions for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 4, 8, 28 and 52</measure>
    <time_frame>Week 4, 8, 28 and 52</time_frame>
    <description>The number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of urgency episodes per 24 hours was calculated as the total number of urgency episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Incontinence Episodes Per 24 Hours at Week 4, 8, 28 and 52</measure>
    <time_frame>Week 4, 8, 28 and 52</time_frame>
    <description>The number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of incontinence episodes per 24 hours was calculated as the total number of incontinence episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Nighttime Micturitions Per 24 Hours at Week 4, 8, 28 and 52</measure>
    <time_frame>Week 4, 8, 28 and 52</time_frame>
    <description>The number of nighttime micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of nighttime micturitions per 24 hours was calculated as the total number of nighttime micturitions for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Voided Volume Per Micturition at Week 4, 8, 28 and 52</measure>
    <time_frame>Week 4, 8, 28 and 52</time_frame>
    <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean voided volume per micturitions was calculated as the total voided volume for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Score of King's Health Questionnaire (KHQ) at Week 28 and 52</measure>
    <time_frame>Week 28 and 52</time_frame>
    <description>KHQ was used to assess the impact of bladder problems on quality of life. The scores ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response. A negative change indicates improvement.
KHQ consists of the following domains:
General health perceptions (GHP)
Impact on life
Role limitations
Physical limitations
Social limitations
Personal relationships (PR)
Emotions
Sleep/energy
Incontinence severity measures (ISM)
Change: mean at Week 28 and 52 minus mean at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Score of Overactive Bladder Questionnaire (OAB-q) at Week 28 and 52</measure>
    <time_frame>Week 28 and 52</time_frame>
    <description>OAB-q was used to assess the extent of subjects who had been botehred by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL). OAB-q consists of the symptom bother score(SBS), the HRQL total score and subscale scores (Coping, Concern, Sleep and Social). The SBS ranges from 0 to 100, where 0=minimal severity and 100=greatest severity (negative change indicates improvement). The HRQL scores range from 0 to 100, where 0=worst outcome and 100=best outcome (positive change indicates improvement).
Change: mean at Week 28 and 52 minus mean at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Shifted in Patient Perception of Bladder Condition (PPBC) Responses From Baseilne to Week 28 and 52 Assessment and Its Percentage</measure>
    <time_frame>Week 28 and 52</time_frame>
    <description>The number of subjects whose perception of bladder condition improved at least by one grade on PPBC from baseline at Week 28 and 52. The PPBC was rated on a 6-point scale as follows:
no problems at all
some very minor problems
some minor problems
some moderate problems
severe problems
many severe problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Grade of PPBC at Week 28 and 52</measure>
    <time_frame>Week 28 and 52</time_frame>
    <description>The PPBC assessment was rated on a 6-point scale as follows:
no problems at all
some very minor problems
some minor problems
some moderate problems
severe problems
many severe problems
Change: mean at Week 28 and 52 minus mean at baseline A negative change indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Fesoterodine fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine fumarate</intervention_name>
    <description>4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks</description>
    <arm_group_label>Fesoterodine fumarate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult OAB patients who present with OAB symptoms, including micturitions &gt;= 8 per day
             and urinary urgency episodes &gt;=1 per day.

        Exclusion Criteria:

          -  Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or
             to peanut or soya or any of the excipients.

          -  Patient has a known neurological disease influencing bladder function.

          -  Patient has a complication of lower urinary tract pathology potentially responsible
             for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic
             organ prolapse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Inegeku, Chibashi</city>
        <state>Chiba-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amagasaki-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaibara-cho, tanba-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Akashi-shi</city>
        <state>Hyougo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuou-ku, koube-shi</city>
        <state>Hyougo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyougo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kawasakishi</city>
        <state>Kanagawaken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nara-shi</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221006&amp;StudyName=Long%20Term%20Study%20To%20Evaluate%20the%20Safety%2C%20Tolerability%20and%20Efficacy%20of%20Fesoterodine%20for%20Overactive%20Bladder.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <results_first_submitted>July 14, 2010</results_first_submitted>
  <results_first_submitted_qc>July 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2010</results_first_posted>
  <last_update_submitted>October 5, 2010</last_update_submitted>
  <last_update_submitted_qc>October 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened at 12 centers in Japan.</recruitment_details>
      <pre_assignment_details>After screening, eligible subjects entered a run-in phase during which they completed a 3-day micturition diary for 3 consecutive days in 7 days prior to Baseline visit. At Baseline visit, the diary data and screening laboratory data were checked against the entry criteria to identify subjects eligible for study participation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total</title>
          <description>All subjects</description>
        </group>
        <group group_id="P2">
          <title>4 mg</title>
          <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
        </group>
        <group group_id="P3">
          <title>4 mg &gt; 8 mg &gt; 4 mg</title>
          <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
        </group>
        <group group_id="P4">
          <title>4 mg &gt; 8 mg</title>
          <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4 mg</title>
          <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
        </group>
        <group group_id="B2">
          <title>4 mg &gt; 8 mg &gt; 4 mg</title>
          <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
        </group>
        <group group_id="B3">
          <title>4 mg &gt; 8 mg</title>
          <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="13.1"/>
                    <measurement group_id="B2" value="54.7" spread="10.5"/>
                    <measurement group_id="B3" value="57.0" spread="11.7"/>
                    <measurement group_id="B4" value="52.7" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4, 8, 28 and 52</title>
        <description>The number of UUI episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of UUI episodes per 24 hours was calculated as the total number of UUI episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 4, 8, 28 and 52</time_frame>
        <population>Of the efficacy analysis set, the subjects whose mean number of UUI episodes per 24 hours at baseline was greater than 0 were analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using last observation carried forward (LOCF) were analyzed. (n=number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4, 8, 28 and 52</title>
          <description>The number of UUI episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of UUI episodes per 24 hours was calculated as the total number of UUI episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
          <population>Of the efficacy analysis set, the subjects whose mean number of UUI episodes per 24 hours at baseline was greater than 0 were analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using last observation carried forward (LOCF) were analyzed. (n=number of analyzable subjects)</population>
          <units>Number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=101, 60, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.48"/>
                    <measurement group_id="O2" value="1.4" spread="1.23"/>
                    <measurement group_id="O3" value="1.7" spread="1.24"/>
                    <measurement group_id="O4" value="2.1" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=101, 60, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="1.104"/>
                    <measurement group_id="O2" value="-0.99" spread="1.117"/>
                    <measurement group_id="O3" value="-0.73" spread="1.281"/>
                    <measurement group_id="O4" value="-0.63" spread="0.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=100, 59, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.293"/>
                    <measurement group_id="O2" value="-1.16" spread="1.173"/>
                    <measurement group_id="O3" value="-1.31" spread="1.450"/>
                    <measurement group_id="O4" value="-1.00" spread="1.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=95, 56, 16, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.282"/>
                    <measurement group_id="O2" value="-1.24" spread="1.185"/>
                    <measurement group_id="O3" value="-1.25" spread="1.518"/>
                    <measurement group_id="O4" value="-1.41" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n= 92, 54, 15, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.553"/>
                    <measurement group_id="O2" value="-1.23" spread="1.228"/>
                    <measurement group_id="O3" value="-1.18" spread="1.661"/>
                    <measurement group_id="O4" value="-1.71" spread="2.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (LOCF) (n=101, 60, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.521"/>
                    <measurement group_id="O2" value="-1.19" spread="1.176"/>
                    <measurement group_id="O3" value="-1.22" spread="1.568"/>
                    <measurement group_id="O4" value="-1.82" spread="2.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Micturitions at Week 4, 8, 28 and 52</title>
        <description>The number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of micturitions per 24 hours was calculated as the total number of micturitions for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 4, 8, 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n=number of anlyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Micturitions at Week 4, 8, 28 and 52</title>
          <description>The number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of micturitions per 24 hours was calculated as the total number of micturitions for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n=number of anlyzable subjects)</population>
          <units>Number of micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="2.85"/>
                    <measurement group_id="O2" value="11.0" spread="2.69"/>
                    <measurement group_id="O3" value="11.2" spread="2.71"/>
                    <measurement group_id="O4" value="12.3" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="1.855"/>
                    <measurement group_id="O2" value="-1.73" spread="1.899"/>
                    <measurement group_id="O3" value="-1.28" spread="1.403"/>
                    <measurement group_id="O4" value="-0.45" spread="1.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=148, 95, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.11" spread="1.946"/>
                    <measurement group_id="O2" value="-2.03" spread="1.897"/>
                    <measurement group_id="O3" value="-1.81" spread="2.035"/>
                    <measurement group_id="O4" value="-2.63" spread="2.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="2.338"/>
                    <measurement group_id="O2" value="-2.18" spread="2.351"/>
                    <measurement group_id="O3" value="-2.06" spread="2.260"/>
                    <measurement group_id="O4" value="-3.02" spread="2.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=133, 84, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.63" spread="2.220"/>
                    <measurement group_id="O2" value="-2.48" spread="2.02"/>
                    <measurement group_id="O3" value="-2.21" spread="2.196"/>
                    <measurement group_id="O4" value="-3.44" spread="2.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (LOCF) (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="2.172"/>
                    <measurement group_id="O2" value="-2.35" spread="1.970"/>
                    <measurement group_id="O3" value="-2.04" spread="2.135"/>
                    <measurement group_id="O4" value="-3.36" spread="2.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 4, 8, 28 and 52</title>
        <description>The number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of urgency episodes per 24 hours was calculated as the total number of urgency episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 4, 8, 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n=number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 4, 8, 28 and 52</title>
          <description>The number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of urgency episodes per 24 hours was calculated as the total number of urgency episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n=number of analyzable subjects)</population>
          <units>Number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.40"/>
                    <measurement group_id="O2" value="3.9" spread="3.31"/>
                    <measurement group_id="O3" value="6.2" spread="3.72"/>
                    <measurement group_id="O4" value="5.1" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="2.009"/>
                    <measurement group_id="O2" value="-1.77" spread="1.856"/>
                    <measurement group_id="O3" value="-1.75" spread="2.572"/>
                    <measurement group_id="O4" value="-1.37" spread="2.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=148, 95, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="2.194"/>
                    <measurement group_id="O2" value="-2.32" spread="1.881"/>
                    <measurement group_id="O3" value="-2.59" spread="2.940"/>
                    <measurement group_id="O4" value="-2.70" spread="2.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="2.597"/>
                    <measurement group_id="O2" value="-2.41" spread="1.855"/>
                    <measurement group_id="O3" value="-3.12" spread="3.304"/>
                    <measurement group_id="O4" value="-2.46" spread="3.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=133, 84, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="2.901"/>
                    <measurement group_id="O2" value="-2.55" spread="2.579"/>
                    <measurement group_id="O3" value="-2.80" spread="3.193"/>
                    <measurement group_id="O4" value="-3.37" spread="3.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (LOCF) (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.61" spread="2.885"/>
                    <measurement group_id="O2" value="-2.30" spread="2.531"/>
                    <measurement group_id="O3" value="-2.93" spread="3.319"/>
                    <measurement group_id="O4" value="-3.40" spread="3.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Incontinence Episodes Per 24 Hours at Week 4, 8, 28 and 52</title>
        <description>The number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of incontinence episodes per 24 hours was calculated as the total number of incontinence episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 4, 8, 28 and 52</time_frame>
        <population>Of the efficacy analysis set, the subjects whose mean number of incontinence episodes per 24 hours at baseline was greater than 0 were analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n= number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Incontinence Episodes Per 24 Hours at Week 4, 8, 28 and 52</title>
          <description>The number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of incontinence episodes per 24 hours was calculated as the total number of incontinence episodes for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
          <population>Of the efficacy analysis set, the subjects whose mean number of incontinence episodes per 24 hours at baseline was greater than 0 were analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n= number of analyzable subjects)</population>
          <units>Number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseilne (n=103, 62, 17,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.74"/>
                    <measurement group_id="O2" value="1.6" spread="1.34"/>
                    <measurement group_id="O3" value="1.8" spread="1.33"/>
                    <measurement group_id="O4" value="2.5" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=103, 62, 17,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="1.140"/>
                    <measurement group_id="O2" value="-0.99" spread="1.166"/>
                    <measurement group_id="O3" value="-0.80" spread="1.225"/>
                    <measurement group_id="O4" value="-0.49" spread="0.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=102, 61, 17, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="1.354"/>
                    <measurement group_id="O2" value="-1.16" spread="1.272"/>
                    <measurement group_id="O3" value="-1.43" spread="1.504"/>
                    <measurement group_id="O4" value="-1.28" spread="1.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n= 97, 58, 16, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="1.476"/>
                    <measurement group_id="O2" value="-1.26" spread="1.322"/>
                    <measurement group_id="O3" value="-1.31" spread="1.542"/>
                    <measurement group_id="O4" value="-1.77" spread="1.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=94, 56, 15, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.589"/>
                    <measurement group_id="O2" value="-1.26" spread="1.331"/>
                    <measurement group_id="O3" value="-1.16" spread="1.847"/>
                    <measurement group_id="O4" value="-1.75" spread="1.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (LOCF) (n=103, 62, 17,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.557"/>
                    <measurement group_id="O2" value="-1.24" spread="1.282"/>
                    <measurement group_id="O3" value="-1.20" spread="1.740"/>
                    <measurement group_id="O4" value="-1.86" spread="1.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Nighttime Micturitions Per 24 Hours at Week 4, 8, 28 and 52</title>
        <description>The number of nighttime micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of nighttime micturitions per 24 hours was calculated as the total number of nighttime micturitions for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 4, 8, 28 and 52</time_frame>
        <population>Of the efficacy analysis set, the subjects whose mean number of nighttime micturitions per 24 hours at baseline was greater than 0 were analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n=number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Nighttime Micturitions Per 24 Hours at Week 4, 8, 28 and 52</title>
          <description>The number of nighttime micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean number of nighttime micturitions per 24 hours was calculated as the total number of nighttime micturitions for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
          <population>Of the efficacy analysis set, the subjects whose mean number of nighttime micturitions per 24 hours at baseline was greater than 0 were analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were also analyzed. (n=number of analyzable subjects)</population>
          <units>Number of micturitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=116, 69, 23, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.04"/>
                    <measurement group_id="O2" value="1.2" spread="1.04"/>
                    <measurement group_id="O3" value="1.6" spread="0.93"/>
                    <measurement group_id="O4" value="1.6" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=116, 69, 23, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.727"/>
                    <measurement group_id="O2" value="-0.34" spread="0.752"/>
                    <measurement group_id="O3" value="-0.45" spread="0.556"/>
                    <measurement group_id="O4" value="-0.08" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=115, 68, 23, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.797"/>
                    <measurement group_id="O2" value="-0.33" spread="0.812"/>
                    <measurement group_id="O3" value="-0.55" spread="0.845"/>
                    <measurement group_id="O4" value="-0.60" spread="0.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=106, 62, 21, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.752"/>
                    <measurement group_id="O2" value="-0.36" spread="0.788"/>
                    <measurement group_id="O3" value="-0.56" spread="0.694"/>
                    <measurement group_id="O4" value="-0.71" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=103, 60, 20, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.807"/>
                    <measurement group_id="O2" value="-0.46" spread="0.904"/>
                    <measurement group_id="O3" value="-0.68" spread="0.546"/>
                    <measurement group_id="O4" value="-0.75" spread="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (LOCF) (n=116, 69, 23, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.826"/>
                    <measurement group_id="O2" value="-0.38" spread="0.908"/>
                    <measurement group_id="O3" value="-0.62" spread="0.614"/>
                    <measurement group_id="O4" value="-0.71" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Voided Volume Per Micturition at Week 4, 8, 28 and 52</title>
        <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean voided volume per micturitions was calculated as the total voided volume for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 4, 8, 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were analyzed. (n=number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Voided Volume Per Micturition at Week 4, 8, 28 and 52</title>
          <description>Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit.
The mean voided volume per micturitions was calculated as the total voided volume for valid diary days divided by the total number of valid diary days collected at that visit.
Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. Only at Week 52, the imputed data for missing values by using LOCF were analyzed. (n=number of analyzable subjects)</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.1" spread="48.09"/>
                    <measurement group_id="O2" value="162.8" spread="48.78"/>
                    <measurement group_id="O3" value="156.1" spread="42.75"/>
                    <measurement group_id="O4" value="143.6" spread="48.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="41.908"/>
                    <measurement group_id="O2" value="20.58" spread="44.357"/>
                    <measurement group_id="O3" value="12.18" spread="43.399"/>
                    <measurement group_id="O4" value="7.16" spread="29.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=148, 95, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.34" spread="51.339"/>
                    <measurement group_id="O2" value="21.86" spread="58.194"/>
                    <measurement group_id="O3" value="23.00" spread="35.061"/>
                    <measurement group_id="O4" value="23.37" spread="38.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.59" spread="46.389"/>
                    <measurement group_id="O2" value="31.98" spread="50.365"/>
                    <measurement group_id="O3" value="40.20" spread="41.613"/>
                    <measurement group_id="O4" value="28.10" spread="36.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=133, 84, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.92" spread="44.007"/>
                    <measurement group_id="O2" value="40.21" spread="47.646"/>
                    <measurement group_id="O3" value="33.02" spread="40.772"/>
                    <measurement group_id="O4" value="24.95" spread="32.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (LOCF) (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.42" spread="45.175"/>
                    <measurement group_id="O2" value="37.08" spread="49.276"/>
                    <measurement group_id="O3" value="28.22" spread="40.693"/>
                    <measurement group_id="O4" value="25.38" spread="31.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Score of King's Health Questionnaire (KHQ) at Week 28 and 52</title>
        <description>KHQ was used to assess the impact of bladder problems on quality of life. The scores ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response. A negative change indicates improvement.
KHQ consists of the following domains:
General health perceptions (GHP)
Impact on life
Role limitations
Physical limitations
Social limitations
Personal relationships (PR)
Emotions
Sleep/energy
Incontinence severity measures (ISM)
Change: mean at Week 28 and 52 minus mean at Baseline</description>
        <time_frame>Week 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Score of King's Health Questionnaire (KHQ) at Week 28 and 52</title>
          <description>KHQ was used to assess the impact of bladder problems on quality of life. The scores ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response. A negative change indicates improvement.
KHQ consists of the following domains:
General health perceptions (GHP)
Impact on life
Role limitations
Physical limitations
Social limitations
Personal relationships (PR)
Emotions
Sleep/energy
Incontinence severity measures (ISM)
Change: mean at Week 28 and 52 minus mean at Baseline</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=number of analyzable subjects)</population>
          <units>Scores on a ascle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GHP: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="21.63"/>
                    <measurement group_id="O2" value="37.1" spread="21.38"/>
                    <measurement group_id="O3" value="37.0" spread="24.07"/>
                    <measurement group_id="O4" value="39.3" spread="20.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHP: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="24.903"/>
                    <measurement group_id="O2" value="-0.57" spread="26.131"/>
                    <measurement group_id="O3" value="0.00" spread="22.613"/>
                    <measurement group_id="O4" value="-9.26" spread="22.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHP: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.22" spread="22.751"/>
                    <measurement group_id="O2" value="-5.88" spread="23.981"/>
                    <measurement group_id="O3" value="-5.68" spread="21.729"/>
                    <measurement group_id="O4" value="-2.78" spread="20.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impact on life: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="23.97"/>
                    <measurement group_id="O2" value="61.2" spread="21.88"/>
                    <measurement group_id="O3" value="68.0" spread="31.15"/>
                    <measurement group_id="O4" value="70.2" spread="22.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impact on life: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.85" spread="27.112"/>
                    <measurement group_id="O2" value="-32.18" spread="24.084"/>
                    <measurement group_id="O3" value="-37.68" spread="33.791"/>
                    <measurement group_id="O4" value="-30.86" spread="30.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impact on life: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.08" spread="29.333"/>
                    <measurement group_id="O2" value="-32.94" spread="26.970"/>
                    <measurement group_id="O3" value="-31.82" spread="33.297"/>
                    <measurement group_id="O4" value="-34.57" spread="33.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="24.75"/>
                    <measurement group_id="O2" value="46.0" spread="23.05"/>
                    <measurement group_id="O3" value="52.0" spread="30.55"/>
                    <measurement group_id="O4" value="50.6" spread="25.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.10" spread="24.733"/>
                    <measurement group_id="O2" value="-28.16" spread="22.777"/>
                    <measurement group_id="O3" value="-33.33" spread="28.427"/>
                    <measurement group_id="O4" value="-23.46" spread="27.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.85" spread="26.732"/>
                    <measurement group_id="O2" value="-30.98" spread="26.371"/>
                    <measurement group_id="O3" value="-31.06" spread="28.310"/>
                    <measurement group_id="O4" value="-25.31" spread="27.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical limitations: Baseline (n=150, 97, 25, 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" spread="26.93"/>
                    <measurement group_id="O2" value="49.8" spread="26.73"/>
                    <measurement group_id="O3" value="54.0" spread="29.38"/>
                    <measurement group_id="O4" value="57.1" spread="25.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical limitations: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.25" spread="26.031"/>
                    <measurement group_id="O2" value="-26.63" spread="25.727"/>
                    <measurement group_id="O3" value="-31.16" spread="29.432"/>
                    <measurement group_id="O4" value="-25.93" spread="24.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical limitations: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.10" spread="25.071"/>
                    <measurement group_id="O2" value="-32.16" spread="24.504"/>
                    <measurement group_id="O3" value="-28.03" spread="25.915"/>
                    <measurement group_id="O4" value="-25.31" spread="26.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social limitations: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="24.36"/>
                    <measurement group_id="O2" value="27.5" spread="23.38"/>
                    <measurement group_id="O3" value="31.1" spread="25.86"/>
                    <measurement group_id="O4" value="39.3" spread="25.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social limitations: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.63" spread="19.410"/>
                    <measurement group_id="O2" value="-17.37" spread="19.241"/>
                    <measurement group_id="O3" value="-22.71" spread="19.955"/>
                    <measurement group_id="O4" value="-24.28" spread="19.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social limitations: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.35" spread="22.661"/>
                    <measurement group_id="O2" value="-20.72" spread="22.245"/>
                    <measurement group_id="O3" value="-24.75" spread="21.668"/>
                    <measurement group_id="O4" value="-25.51" spread="25.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: Baseline (n=124, 82, 18, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="22.46"/>
                    <measurement group_id="O2" value="17.3" spread="20.86"/>
                    <measurement group_id="O3" value="16.7" spread="22.87"/>
                    <measurement group_id="O4" value="29.2" spread="25.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: Week 28 (n=110, 71, 16, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.18" spread="18.354"/>
                    <measurement group_id="O2" value="-11.74" spread="18.558"/>
                    <measurement group_id="O3" value="-10.42" spread="17.078"/>
                    <measurement group_id="O4" value="-19.57" spread="17.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR: Week 52 (n=109, 70, 16, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.68" spread="19.342"/>
                    <measurement group_id="O2" value="-13.57" spread="19.514"/>
                    <measurement group_id="O3" value="-12.50" spread="17.743"/>
                    <measurement group_id="O4" value="-19.57" spread="19.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotions: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="28.38"/>
                    <measurement group_id="O2" value="49.1" spread="27.49"/>
                    <measurement group_id="O3" value="52.0" spread="32.19"/>
                    <measurement group_id="O4" value="57.5" spread="27.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotions: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.49" spread="24.219"/>
                    <measurement group_id="O2" value="-27.84" spread="23.163"/>
                    <measurement group_id="O3" value="-27.54" spread="26.137"/>
                    <measurement group_id="O4" value="-26.34" spread="26.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotions: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.27" spread="26.434"/>
                    <measurement group_id="O2" value="-32.42" spread="24.799"/>
                    <measurement group_id="O3" value="-26.26" spread="28.595"/>
                    <measurement group_id="O4" value="-26.75" spread="29.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep/energy: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="27.44"/>
                    <measurement group_id="O2" value="33.2" spread="24.00"/>
                    <measurement group_id="O3" value="37.3" spread="29.77"/>
                    <measurement group_id="O4" value="50.0" spread="33.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep/energy: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.61" spread="21.586"/>
                    <measurement group_id="O2" value="-17.43" spread="19.998"/>
                    <measurement group_id="O3" value="-18.12" spread="26.070"/>
                    <measurement group_id="O4" value="-22.84" spread="22.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep/energy: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.27" spread="23.338"/>
                    <measurement group_id="O2" value="-20.59" spread="22.219"/>
                    <measurement group_id="O3" value="-15.91" spread="22.700"/>
                    <measurement group_id="O4" value="-27.78" spread="26.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISM: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="20.39"/>
                    <measurement group_id="O2" value="32.6" spread="18.83"/>
                    <measurement group_id="O3" value="31.5" spread="18.51"/>
                    <measurement group_id="O4" value="45.7" spread="24.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISM: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.25" spread="17.223"/>
                    <measurement group_id="O2" value="-14.87" spread="16.541"/>
                    <measurement group_id="O3" value="-16.81" spread="17.623"/>
                    <measurement group_id="O4" value="-20.25" spread="18.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISM: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.00" spread="19.199"/>
                    <measurement group_id="O2" value="-18.43" spread="18.392"/>
                    <measurement group_id="O3" value="-14.55" spread="19.370"/>
                    <measurement group_id="O4" value="-24.44" spread="21.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Score of Overactive Bladder Questionnaire (OAB-q) at Week 28 and 52</title>
        <description>OAB-q was used to assess the extent of subjects who had been botehred by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL). OAB-q consists of the symptom bother score(SBS), the HRQL total score and subscale scores (Coping, Concern, Sleep and Social). The SBS ranges from 0 to 100, where 0=minimal severity and 100=greatest severity (negative change indicates improvement). The HRQL scores range from 0 to 100, where 0=worst outcome and 100=best outcome (positive change indicates improvement).
Change: mean at Week 28 and 52 minus mean at baseline</description>
        <time_frame>Week 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Score of Overactive Bladder Questionnaire (OAB-q) at Week 28 and 52</title>
          <description>OAB-q was used to assess the extent of subjects who had been botehred by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL). OAB-q consists of the symptom bother score(SBS), the HRQL total score and subscale scores (Coping, Concern, Sleep and Social). The SBS ranges from 0 to 100, where 0=minimal severity and 100=greatest severity (negative change indicates improvement). The HRQL scores range from 0 to 100, where 0=worst outcome and 100=best outcome (positive change indicates improvement).
Change: mean at Week 28 and 52 minus mean at baseline</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=analyzable subjects)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBS: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="22.53"/>
                    <measurement group_id="O2" value="37.4" spread="19.74"/>
                    <measurement group_id="O3" value="45.2" spread="21.04"/>
                    <measurement group_id="O4" value="58.7" spread="25.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBS: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.13" spread="19.835"/>
                    <measurement group_id="O2" value="-22.30" spread="18.588"/>
                    <measurement group_id="O3" value="-27.07" spread="16.231"/>
                    <measurement group_id="O4" value="-32.59" spread="24.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBS: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.24" spread="20.287"/>
                    <measurement group_id="O2" value="-22.41" spread="17.616"/>
                    <measurement group_id="O3" value="-21.25" spread="16.597"/>
                    <measurement group_id="O4" value="-37.41" spread="26.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Total: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="18.31"/>
                    <measurement group_id="O2" value="73.9" spread="16.66"/>
                    <measurement group_id="O3" value="72.2" spread="18.97"/>
                    <measurement group_id="O4" value="58.4" spread="18.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Total: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.66" spread="14.711"/>
                    <measurement group_id="O2" value="14.26" spread="13.366"/>
                    <measurement group_id="O3" value="16.00" spread="14.787"/>
                    <measurement group_id="O4" value="19.88" spread="18.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Total: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.92" spread="16.461"/>
                    <measurement group_id="O2" value="15.99" spread="14.717"/>
                    <measurement group_id="O3" value="13.35" spread="14.961"/>
                    <measurement group_id="O4" value="22.76" spread="21.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Coping: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6" spread="26.07"/>
                    <measurement group_id="O2" value="65.6" spread="24.59"/>
                    <measurement group_id="O3" value="64.6" spread="26.49"/>
                    <measurement group_id="O4" value="45.1" spread="25.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Coping: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.86" spread="20.008"/>
                    <measurement group_id="O2" value="19.66" spread="17.871"/>
                    <measurement group_id="O3" value="18.15" spread="18.605"/>
                    <measurement group_id="O4" value="27.04" spread="26.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Coping: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.75" spread="23.773"/>
                    <measurement group_id="O2" value="20.91" spread="21.821"/>
                    <measurement group_id="O3" value="15.00" spread="18.127"/>
                    <measurement group_id="O4" value="29.91" spread="31.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Concern: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="21.54"/>
                    <measurement group_id="O2" value="73.9" spread="19.70"/>
                    <measurement group_id="O3" value="72.5" spread="20.90"/>
                    <measurement group_id="O4" value="59.5" spread="24.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Concern: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.48" spread="18.180"/>
                    <measurement group_id="O2" value="16.95" spread="17.142"/>
                    <measurement group_id="O3" value="21.24" spread="17.943"/>
                    <measurement group_id="O4" value="21.06" spread="21.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Concern: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.77" spread="18.400"/>
                    <measurement group_id="O2" value="19.23" spread="16.946"/>
                    <measurement group_id="O3" value="16.49" spread="17.961"/>
                    <measurement group_id="O4" value="24.13" spread="22.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Sleep: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" spread="23.95"/>
                    <measurement group_id="O2" value="69.9" spread="22.30"/>
                    <measurement group_id="O3" value="65.8" spread="25.61"/>
                    <measurement group_id="O4" value="55.6" spread="25.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Sleep: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.41" spread="21.808"/>
                    <measurement group_id="O2" value="11.13" spread="21.579"/>
                    <measurement group_id="O3" value="13.22" spread="19.313"/>
                    <measurement group_id="O4" value="15.85" spread="24.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Sleep: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.90" spread="21.467"/>
                    <measurement group_id="O2" value="13.32" spread="19.629"/>
                    <measurement group_id="O3" value="13.09" spread="19.873"/>
                    <measurement group_id="O4" value="21.33" spread="27.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Social: Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" spread="14.17"/>
                    <measurement group_id="O2" value="91.2" spread="12.31"/>
                    <measurement group_id="O3" value="90.6" spread="13.71"/>
                    <measurement group_id="O4" value="81.0" spread="17.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQ- Social: Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="11.461"/>
                    <measurement group_id="O2" value="5.01" spread="10.064"/>
                    <measurement group_id="O3" value="8.00" spread="13.156"/>
                    <measurement group_id="O4" value="10.81" spread="13.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRQL-Social: Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="12.277"/>
                    <measurement group_id="O2" value="6.26" spread="10.537"/>
                    <measurement group_id="O3" value="6.55" spread="12.802"/>
                    <measurement group_id="O4" value="10.81" spread="16.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Shifted in Patient Perception of Bladder Condition (PPBC) Responses From Baseilne to Week 28 and 52 Assessment and Its Percentage</title>
        <description>The number of subjects whose perception of bladder condition improved at least by one grade on PPBC from baseline at Week 28 and 52. The PPBC was rated on a 6-point scale as follows:
no problems at all
some very minor problems
some minor problems
some moderate problems
severe problems
many severe problems</description>
        <time_frame>Week 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=number of analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Shifted in Patient Perception of Bladder Condition (PPBC) Responses From Baseilne to Week 28 and 52 Assessment and Its Percentage</title>
          <description>The number of subjects whose perception of bladder condition improved at least by one grade on PPBC from baseline at Week 28 and 52. The PPBC was rated on a 6-point scale as follows:
no problems at all
some very minor problems
some minor problems
some moderate problems
severe problems
many severe problems</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=number of analyzable subjects)</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Grade of PPBC at Week 28 and 52</title>
        <description>The PPBC assessment was rated on a 6-point scale as follows:
no problems at all
some very minor problems
some minor problems
some moderate problems
severe problems
many severe problems
Change: mean at Week 28 and 52 minus mean at baseline A negative change indicates improvement.</description>
        <time_frame>Week 28 and 52</time_frame>
        <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=analyzable subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Grade of PPBC at Week 28 and 52</title>
          <description>The PPBC assessment was rated on a 6-point scale as follows:
no problems at all
some very minor problems
some minor problems
some moderate problems
severe problems
many severe problems
Change: mean at Week 28 and 52 minus mean at baseline A negative change indicates improvement.</description>
          <population>The efficacy analysis set (those who took at least one dose of study drug and contributed data to baseline and at least one valid post-baseline efficacy assessment) was analyzed. Observed values were used for the analyses. (n=analyzable subjects)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=150, 97, 25, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.51"/>
                    <measurement group_id="O2" value="4.2" spread="0.43"/>
                    <measurement group_id="O3" value="4.5" spread="0.65"/>
                    <measurement group_id="O4" value="4.4" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=137, 87, 23, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="1.166"/>
                    <measurement group_id="O2" value="-1.74" spread="1.094"/>
                    <measurement group_id="O3" value="-1.83" spread="0.937"/>
                    <measurement group_id="O4" value="-1.26" spread="1.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=134, 85, 22, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="1.141"/>
                    <measurement group_id="O2" value="-1.85" spread="1.139"/>
                    <measurement group_id="O3" value="-1.59" spread="1.054"/>
                    <measurement group_id="O4" value="-1.70" spread="1.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume</title>
        <description>The number of subjects who experienced AEs (all causality and treatment-related ) based on safety assessment during the study were summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.</description>
        <time_frame>52 Weeks</time_frame>
        <population>The safety analysis set (all subjects who took at least one dose of study drug) was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All subjects</description>
          </group>
          <group group_id="O2">
            <title>4 mg</title>
            <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
          </group>
          <group group_id="O3">
            <title>4 mg &gt; 8 mg &gt; 4 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
          </group>
          <group group_id="O4">
            <title>4 mg &gt; 8 mg</title>
            <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume</title>
          <description>The number of subjects who experienced AEs (all causality and treatment-related ) based on safety assessment during the study were summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.</description>
          <population>The safety analysis set (all subjects who took at least one dose of study drug) was analyzed.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-causality AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to all-causlity AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DR/TD due to all-causality AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DR/TD due to treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 Weeks</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Total</title>
          <description>All subjects</description>
        </group>
        <group group_id="E2">
          <title>4 mg</title>
          <description>Remained on a dose of fesoterodine 4 mg for the entire treatment period (subjects who remained on a dose of 4 mg)</description>
        </group>
        <group group_id="E3">
          <title>4 mg &gt; 8 mg &gt; 4 mg</title>
          <description>Increased to fesoterodine 8 mg at Week 4 and reduced to 4 mg at Week 8 (subjects whose dose was increased to 8 mg and then reduced to 4 mg)</description>
        </group>
        <group group_id="E4">
          <title>4 mg &gt; 8 mg</title>
          <description>Increased to fesoterodine 8 mg at Week 4 and remained on a dose of 8 mg after Week 4 (subjects whose dose was increased to 8 mg and maintained)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Residual urine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

